Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The Jama data shows mOS went down when they removed the control group. Do you not understand that is bad for the trial? And shills will claim "look at the long tail". GBM is a long tail disease. That long tail consists of prognostic factors that were excluded from much of the ECA which didn't even have patient level data to compare. It showed in the IMUC and CLDX data too. But it also showed in those trial's control arms because they were of the same patient population.
Keep attacking those who actually understand the data simply because you don't.
Let me summarize. The trial was a poorly designed mess and the garbage ECA will make evaluating the random pieces impossible.
I'd love a list of how many times longs said NWBO was gonna (since 2012)
1) Get bought out by big pharma
2) partner with big pharma
3) submit a BLA
4) go over $2
5) go over $5
6) go over $10
7) merge with Cognate
8) merge with Advent
9) burn shorts
10) get AF arrested
Zero ORR for failed Direct. Sunkist has grapefruit juice which shows a better response.
They are comparable in that they both lied about the futility rec and the data sucks for both. That's enough.
Investing in trials they get futilit holds from the FDA, have predefined endpoints fail and OS between the randomized arms fails is a questionable move.
It would take the FDA 3 minutes to reject this trash trial as a poorly designed, poorly controlled, ad-hoc mess.
Shills always shilling.
This OTC penny stock trades 2.5 million a day, only bumped up over 2 million from the recent pump and dump.
Trading isn't the problem. A crappy company that can't finish a 15 year old trial is the problem.
Where are you getting this 65%? The Jama article shows 11% 30 month survival in the treatment arm. That's 7 patients of the 64. 32 patients of the 640 ECA with wildly different inclusion criteria (like actual rGBM) lived 30 months after recurrence.
and 11.1% vs 5.1% were alive at 30 months after recurrence.
They aren't running DCVax only trials on GBM patients and haven't for a long time because they know it doesn't work.
They recently hyped combo trial here stopped enrolling in 2014.
It ain't aimed at me. Nobody except friendlies are shorting this turd to hedge. Exactly how the pump and dumps are planned. Besides, I made money on this, because it's a stock, and smart investors sell stock to make money when it goes up. 2015-2018 it was easy to chart the pump and dumps because the PRs came out like clockwork and the accompanying dump (many times by the company) followed.
Yep. The goal is to completely finance the buildout of Advent, just like Cognate, so Linda Powers can sell it, just like Cognate. All on the backs of shareholders, only benefitting LP and her cronies.
It is not to help GBM patients, and hasn't been since they got the futility recommendation in 2015 during the interim analysis.
It's not nonsensical if one is too stupid to understand it. It's a you problem.
With your BS history of share purchases, there shouldn't be over a billion float because you should own it all.
Why is it you always attack those who are not shills for the company but never post anything positive about the company? Their pay can't be that good. They only pay Big booz a couple hundred a show. They can't possibly be paying you better than that.
It's a bot/scraper.
Just admit you didn't read it.
It was a tiny trial, with 23 patients and only 5 patients with GBM treated with Poly ICLC. The longest surviving GBM patient in this was on placebo. The data is from 2010-2014 so like everything involved with DCVax, it takes a decade to produce ANYTHING.
From the discussion:
Although this was a randomized study, it was powered for immune biomarker analysis, not for survival. As such, the clinical efficacy outcomes should be interpreted with caution. Given the noted long-term survival with the adjuvant use of poly-ICLC with DC vaccination, particularly in the grade III cohort of patients, further clinical trials that incorporate these combinations of immunotherapeutic agents are warranted.
Keep naming people that weren’t in the trial that used multiple different treatments.
How about someone from the last 10 years? Oh, that’s right, they keep wheeling out the same 3 people. Littering the infomercial theater with dead bodies wouldn’t be a good look.
The company is only dealing with one issue. The same one they’ve been dealing with since they launched this trial 15 years ago. DCvax doesn’t work.
They will need to run a trial with the criteria you claim helps DCvax work in the long tail against the same patient criteria taking a placebo to PROVE it works. Literally the whole point of running a P3.
Considering they don’t even have patient level data for the BS control arm they sure as hell didn’t prove it in this shitshow trial.
It took them a year to translate a document from English to German so stupid excuses is their forte.
Why? Are you asking if he's an idiot for holding this turd long?
You forgot his other alias when he got banned. Something like "Imanass$$mith".
Because it's not at zero.
I also recommend you to review the new definition of GBM that doesn't include IDH mutant patients
65 % (n=15) had diagnoses of IDH wild type glioblastoma (WHO Grade IV)
Make some more stupid share prognostications. I'm sure you've been guessing on SP for the last 10 years, every time it comes up and the board says $25+ and you join in. The only thing that will happen once (if) a submission occurs is a rejection and a refusal to file.
Like this share price? $1.15 when they released TLD. So congrats on a 35% loss with such stellar results.
So where’s the 10%, or even 5%, Learning Curve is always going on about?
Congratulations. Two things that don't work are actually the same.
It's really irrelevant. Neither one works, especially as a monotherapy and most likely not as a combo either. So another 10 years before a P3 combo trial is run, and probably just as half-assed.
First off , ex didn't make the majority of those predictions, and he has always stated they would submit something and it would be a failure. They've submitted nothing yet, and it will be rejected anyway.
That said, since you are talking about predictions, now do literally every long's predictions on:
1)SP (over $10, over $100, yada yada)
2) submission to every RA
3) partnership
4) buyout
5) approval and replace SOC (since 2016)
6) acquisition of Cognate
7) acquisition of Advent
8) patents proving
9) shipping labels proving
10) job openings meaning
The company is free to run another 15 year trial, get a futility rec during the IA on that one too, wait til year 13, then change the endpoints to make it look like DCVax-L alone works though they already know it doesn't. They made their own blueprint.
The combo trials five years ago which also produced nothing, used DCVax-Placebo too.
Shiny new object. Since the data sucked, it went from the P3 to spoofing. Then it was "gonna submit something in the future to someone." And now bagholders gotta hype up early stage combo trials again.
I think we are about due for them to dust off Direct and it's ZERO ORR for some sort of PR.
Supply and demand is ridiculous? It's simple. Nobody wants to pay over .61. This only traded 2 million shares when the price went UP. Was that ridiculous?
The company pumped, friendlies dumped, and retail traders got stuck.
What makes them "of the best" of anything?
They are the "best of" because they are involved in the same piece of crap as you are.
Let's randomly take one of these "best NEURO-ONC".
Scott M. Lindhorst, MD
Let's Google him.
Results:
Well looky here. If you go to the South Carolina contacts for this Optune trial, what do we find?
Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant With RT & TMZ for the Treatment of Newly Diagnosed GBM (EF-32)
South Carolina
Charleston, South Carolina, United States, 29425
Recruiting
MUSC Radiation Oncology Brain & Spine Tumor Program
Contact:
Scott Lindhorst, MD
Phone Number: 843-792-9016
Email: lindhors@musc.edu
Philadelphia, Pennsylvania, United States, 19104
Not yet recruiting
University of Pennsylvania
Contact:
Steven Brem, MD
Phone Number: 215-662-3487
Email: steven.brem@uphs.upenn.edu
The same LP who said the company had the capacity with Cognate to handle production after approval?
The same LP who said the company temporarily halted screening of the P3 trial when the FDA made them halt screening. The same LP who apparently things "temporarily" means "forever".
Shall l go over all times LP said "soon' starting in around 2016 when asked when the trial would finish?
Quoting LP as a proof of truth is like you quoting your own bullshit on twitter or reddit as a source.
He has always said there will be a submission. So they can kick the can down the road more and let people like you make excuses when it gets rejected and blame the bogey man like BP, corrupt FDA employees, etc after RAs explain to them the data sucked, the trial design sucked, and the company sucks (at everything but making LP rich by churning out CDMOs).
He certainly understands that the company admitted to the futility rec in the Jama article and that the mOS got worse when they removed the control patients.
You understand not to post nearly as much now that you aren't paid .03 for every post deletion.
The FDA has also made clear the criteria for ECAs and this trial fails on many. They probably told NWBO not to bother without many additional changes the company can not afford or knows would expose the failure quickly.